 Victoria Martucci
Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Paraganglioma | 12 | 2017 | 64 | 1.770 |
Why?
| | Succinate Dehydrogenase | 10 | 2017 | 66 | 1.620 |
Why?
| | Adrenal Gland Neoplasms | 10 | 2017 | 98 | 1.250 |
Why?
| | Pheochromocytoma | 9 | 2017 | 67 | 1.180 |
Why?
| | Paraganglioma, Extra-Adrenal | 3 | 2015 | 9 | 0.660 |
Why?
| | Germ-Line Mutation | 3 | 2017 | 176 | 0.540 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 919 | 0.480 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2015 | 18 | 0.470 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2015 | 260 | 0.450 |
Why?
| | Heart Neoplasms | 1 | 2015 | 56 | 0.420 |
Why?
| | Genome-Wide Association Study | 1 | 2021 | 1378 | 0.420 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2021 | 2146 | 0.410 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2355 | 0.380 |
Why?
| | Mutation | 4 | 2015 | 4093 | 0.300 |
Why?
| | Positron-Emission Tomography | 4 | 2015 | 343 | 0.300 |
Why?
| | DNA Mutational Analysis | 2 | 2015 | 409 | 0.210 |
Why?
| | Tennessee | 1 | 2021 | 57 | 0.170 |
Why?
| | Thyroid Diseases | 1 | 2021 | 44 | 0.170 |
Why?
| | Linkage Disequilibrium | 1 | 2021 | 249 | 0.160 |
Why?
| | Multifactorial Inheritance | 1 | 2021 | 190 | 0.150 |
Why?
| | Radiopharmaceuticals | 3 | 2015 | 207 | 0.150 |
Why?
| | Middle Aged | 14 | 2021 | 36176 | 0.140 |
Why?
| | Head and Neck Neoplasms | 2 | 2014 | 562 | 0.140 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2014 | 161 | 0.140 |
Why?
| | Dideoxynucleosides | 2 | 2015 | 24 | 0.140 |
Why?
| | Adult | 15 | 2021 | 40707 | 0.140 |
Why?
| | Genetic Testing | 3 | 2015 | 480 | 0.130 |
Why?
| | Neoplasm Metastasis | 3 | 2015 | 691 | 0.130 |
Why?
| | Dihydroxyphenylalanine | 2 | 2014 | 11 | 0.130 |
Why?
| | Dopamine | 3 | 2015 | 295 | 0.130 |
Why?
| | Immunotherapy | 1 | 2021 | 667 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1659 | 0.120 |
Why?
| | Metanephrine | 2 | 2012 | 4 | 0.120 |
Why?
| | Male | 18 | 2021 | 72817 | 0.120 |
Why?
| | Phenotype | 2 | 2021 | 3157 | 0.110 |
Why?
| | Female | 17 | 2021 | 78763 | 0.110 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2015 | 54 | 0.110 |
Why?
| | Bone Neoplasms | 2 | 2015 | 256 | 0.100 |
Why?
| | Aged | 10 | 2021 | 26125 | 0.100 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2014 | 37 | 0.100 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2014 | 47 | 0.100 |
Why?
| | Humans | 22 | 2021 | 145491 | 0.100 |
Why?
| | Normetanephrine | 1 | 2012 | 4 | 0.090 |
Why?
| | Young Adult | 8 | 2017 | 14192 | 0.090 |
Why?
| | 3-Iodobenzylguanidine | 1 | 2012 | 13 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1188 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 342 | 0.090 |
Why?
| | Proteins | 1 | 2018 | 1020 | 0.090 |
Why?
| | Autoimmunity | 1 | 2018 | 936 | 0.090 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 105 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1710 | 0.090 |
Why?
| | Iodine Radioisotopes | 1 | 2012 | 137 | 0.090 |
Why?
| | Risk Factors | 3 | 2021 | 10874 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 452 | 0.080 |
Why?
| | Thyroid Neoplasms | 1 | 2014 | 349 | 0.080 |
Why?
| | Adolescent | 8 | 2017 | 22485 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2664 | 0.070 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1321 | 0.070 |
Why?
| | Child | 7 | 2017 | 22680 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2021 | 17269 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2772 | 0.060 |
Why?
| | Whole Body Imaging | 2 | 2015 | 29 | 0.050 |
Why?
| | Chemical Industry | 1 | 2004 | 9 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 2 | 2015 | 145 | 0.050 |
Why?
| | Hazardous Substances | 1 | 2004 | 16 | 0.050 |
Why?
| | Hypertension | 1 | 2012 | 1273 | 0.050 |
Why?
| | Multimodal Imaging | 2 | 2014 | 129 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2017 | 8326 | 0.040 |
Why?
| | Survival Analysis | 2 | 2015 | 1374 | 0.040 |
Why?
| | Prognosis | 3 | 2015 | 4323 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3897 | 0.040 |
Why?
| | Residence Characteristics | 1 | 2004 | 376 | 0.040 |
Why?
| | Saint Vincent and the Grenadines | 1 | 2019 | 1 | 0.040 |
Why?
| | Trinidad and Tobago | 1 | 2019 | 5 | 0.040 |
Why?
| | History, 16th Century | 1 | 2019 | 15 | 0.040 |
Why?
| | History, 15th Century | 1 | 2019 | 11 | 0.040 |
Why?
| | History, 18th Century | 1 | 2019 | 18 | 0.040 |
Why?
| | History, Ancient | 1 | 2019 | 55 | 0.040 |
Why?
| | History, 19th Century | 1 | 2019 | 63 | 0.040 |
Why?
| | Chromosomes, Human, Y | 1 | 2019 | 37 | 0.040 |
Why?
| | Human Migration | 1 | 2019 | 26 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2004 | 577 | 0.040 |
Why?
| | Genetics, Population | 1 | 2019 | 217 | 0.030 |
Why?
| | DNA, Mitochondrial | 1 | 2019 | 212 | 0.030 |
Why?
| | Penetrance | 1 | 2017 | 30 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 3340 | 0.030 |
Why?
| | Tissue Fixation | 1 | 2015 | 36 | 0.030 |
Why?
| | Child, Preschool | 3 | 2017 | 11837 | 0.030 |
Why?
| | Paraffin Embedding | 1 | 2015 | 31 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2017 | 369 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3759 | 0.030 |
Why?
| | Reference Standards | 1 | 2015 | 178 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2015 | 196 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2014 | 26 | 0.030 |
Why?
| | Radioactive Tracers | 1 | 2013 | 5 | 0.030 |
Why?
| | Adrenal Medulla | 1 | 2013 | 10 | 0.020 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2013 | 26 | 0.020 |
Why?
| | Glycolysis | 1 | 2015 | 342 | 0.020 |
Why?
| | Injections | 1 | 2014 | 200 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2130 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2012 | 123 | 0.020 |
Why?
| | DNA | 1 | 2019 | 1451 | 0.020 |
Why?
| | Biological Transport | 1 | 2013 | 422 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2012 | 61 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 41 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2013 | 191 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 262 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2013 | 306 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 294 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 380 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2013 | 339 | 0.020 |
Why?
| | Case-Control Studies | 2 | 2012 | 3619 | 0.020 |
Why?
| | Reference Values | 1 | 2012 | 797 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 780 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 426 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 848 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1544 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2129 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1896 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2013 | 461 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 631 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2014 | 482 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1853 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2015 | 779 | 0.020 |
Why?
| | Neoplasms | 1 | 2004 | 2897 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2499 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 2002 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1164 | 0.020 |
Why?
| | United States | 2 | 2015 | 16115 | 0.020 |
Why?
| | Sex Factors | 1 | 2012 | 2110 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 11831 | 0.010 |
Why?
| | Italy | 1 | 2004 | 114 | 0.010 |
Why?
| | Pleural Neoplasms | 1 | 2004 | 30 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6437 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 5426 | 0.010 |
Why?
| | Lymphoma | 1 | 2004 | 234 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2004 | 168 | 0.010 |
Why?
| | Cause of Death | 1 | 2004 | 469 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10064 | 0.010 |
Why?
| | Odds Ratio | 1 | 2004 | 1082 | 0.010 |
Why?
| | Models, Statistical | 1 | 2004 | 679 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 2915 | 0.010 |
Why?
|
|
Martucci's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|